Home › Funds › Affinity Asset Advisors, LLC › RLAY
Affinity Asset Advisors, LLC position in RLAY
RELAY THERAPEUTICS INC · Health Care
Affinity Asset Advisors, LLC reported holding 850,000 shares of RLAY (RELAY THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$15.3M, representing 0.71% of its reported portfolio and ranking #37 among its reported holdings. Affinity Asset Advisors, LLC has disclosed RLAY holdings in 4 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's RLAY position evolved
Affinity Asset Advisors, LLC first disclosed a stake in RLAY in Q4 2023 at 300,000 shares (US$3.3M). The position peaked in Q2 2026 at 1,050,000 shares, worth US$19.6M. Across 4 filings, Affinity Asset Advisors, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 850,000 shares valued at US$15.3M — a reduction of -200,000 shares quarter over quarter.. Notable position changes include a 162% increase in Q2 2026 (shares fell 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 300.00K | $3.30M | New |
| Q1 2026 | 400.00K | $3.98M | New |
| Q2 2026 | 1.05M | $19.65M | Add |
| Q3 2026 | 850.00K | $15.34M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RLAY and 13F data
RLAY (RELAY THERAPEUTICS INC) is a Health Care company. 60 other funds we track also report a position in RLAY — the largest reported positions include SB INVESTMENT ADVISERS (UK) LTD (US$522.1M), Casdin Capital (US$300.0M), PERCEPTIVE ADVISORS LLC (US$263.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RLAY
- SB INVESTMENT ADVISERS (UK) LTD 27.90M sh · $522.10M · Q2 2026
- Casdin Capital 16.04M sh · $300.02M · Q2 2026
- PERCEPTIVE ADVISORS LLC 14.11M sh · $263.93M · Q2 2026
- Commodore Capital LP 12.00M sh · $224.52M · Q2 2026
- Nextech Invest Ltd. 6.78M sh · $126.79M · Q2 2026
- Bellevue Group AG 6.19M sh · $115.74M · Q2 2026
- TCG Crossover Management, LLC 4.27M sh · $79.95M · Q2 2026
- Kynam Capital Management, LP 3.30M sh · $61.74M · Q2 2026
- Siren, L.L.C. 3.26M sh · $58.90M · Q3 2026
- Spruce Street Capital LP 2.98M sh · $53.86M · Q3 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $52.89M · Q2 2026
- MPM BioImpact LLC 2.42M sh · $45.20M · Q2 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held RLAY?
Affinity Asset Advisors, LLC has disclosed RLAY holdings in 4 of the last 12 reported quarters, going back to Q4 2023.
What is Affinity Asset Advisors, LLC's current position in RLAY?
As of Q3 2026, Affinity Asset Advisors, LLC holds 850.00K shares of RLAY (RELAY THERAPEUTICS INC), valued at $15.34M, representing 0.71% of its reported portfolio and ranking #37.
Has Affinity Asset Advisors, LLC been buying or selling RLAY?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC reduced its position in RLAY. The position peaked in Q2 2026 at 1.05M shares.
Which other funds hold RLAY?
Other major institutional holders of RLAY include SB INVESTMENT ADVISERS (UK) LTD, Casdin Capital, PERCEPTIVE ADVISORS LLC, among 60 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.